Adding Pembrolizumab To Preoperative Radiotherapy and Surgery Improves DFS for Patients with Stage III Soft Tissue Sarcomas of the Extremity By Ogkologos - December 2, 2024 965 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SU2C-SARC032 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR FDA Approves Belzutifan for Advanced Renal Cell Carcinoma January 19, 2024 Adding Avelumab to Preoperative Chemoradiotherapy Provides Promising Anti-Tumour Activity in Locally... July 8, 2021 Neoadjuvant Nivolumab Plus Chemotherapy Results in Significantly Longer Event-Free Survival in... May 3, 2022 Workout Wednesdays – Leg Exercises Part 3 June 24, 2020 Load more HOT NEWS Precision drug slows progression of advanced breast cancer Higher Pregnancy Rates and No Impact on Prognosis with Embryo/Oocyte Cryopreservation... FDA Approves Pembrolizumab with Enfortumab Vedotin-ejfv for Muscle Invasive Bladder Cancer Withdrawal of the Application to Change the EMA Marketing Authorisation for...
